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We previously reported the Bruton’s tyrosine kinase (BTK) inhibitors ibrutinib and
acalabrutinib improve outcomes in a mouse model of polymicrobial sepsis. Now we
show that genetic deficiency of the BTK gene alone in Xid mice confers protection
against cardiac, renal, and liver injury in polymicrobial sepsis and reduces hyperimmune
stimulation (“cytokine storm”) induced by an overwhelming bacterial infection. Protection
is due in part to enhanced bacterial phagocytosis in vivo, changes in lipid metabolism and
decreased activation of NF-κB and the NLRP3 inflammasome. The inactivation of BTK
leads to reduced innate immune cell recruitment and a phenotypic switch from M1 to M2
macrophages, aiding in the resolution of sepsis. We have also found that BTK expression
in humans is increased in the blood of septic non-survivors, while lower expression is
associated with survival from sepsis. Importantly no further reduction in organ damage,
cytokine production, or changes in plasma metabolites is seen in Xid mice treated with
the BTK inhibitor ibrutinib, demonstrating that the protective effects of BTK inhibitors in
polymicrobial sepsis are mediated solely by inhibition of BTK and not by off-target effects
of this class of drugs.
Keywords: X-linked immunodeficient mice, Bruton’s tyrosine kinase (BTK), sepsis, ibrutinib, cytokine storm,
phagocytosis, NF-κB, NLRP3 inflammasome
INTRODUCTION
Sepsis is a common and life-threatening condition caused by a dysregulated host response to an
infection, either bacterial, fungal, or viral (1). Sepsis is a major public health problem leading to
multiple organ dysfunction and death. Globally there are 50 million cases of sepsis resulting in
the death of 11 million people every year representing 20% of all deaths worldwide (2). Despite
intensive, supportive care, and current treatments (antibiotic therapy and fluid resuscitation), no
targeted therapies have proven effective at reducing mortality (3, 4). There is an urgent need for the
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development of pharmacological treatments for sepsis-induced
organ dysfunction (5).
Bruton’s tyrosine kinase (BTK) is well-known as a critical
component of the B-cell antigen receptor (BCR) signaling
pathway (6). BTK is also involved in the activation of the
toll-like receptor (TLR) signaling pathways (by binding to the
TIR domain of TLR4 and TLR’s adaptor molecules MyD88,
and Mal) and the NLRP3 inflammasome (by binding to the
ASC component) (7–9). Activation of both the TLR signaling
pathway and the NLRP3 inflammasome play a pivotal role in
the pathophysiology of sepsis (10, 11). The expression of BTK
is not restricted to B cells, as BTK is also expressed in cells of
myeloid lineage, includingmacrophages and neutrophils (12, 13),
activation of which contributes to the pathophysiology of sepsis.
We have recently shown that the BTK inhibitors ibrutinib
(first generation) and acalabrutinib (more selective, second
generation) attenuate the systemic inflammation (“cytokine
storm”) and the multiple organ failure caused by sepsis in
mice (14). Ibrutinib is already approved for the use in chronic
lymphatic leukemia, mantle cell lymphoma, Waldenstrom
macroglobulinemia, and graft vs. host disease (15) and
acalabrutinib in mantle cell lymphoma (16). The recent COVID-
19 pandemic has driven the search for drugs that can be
repurposed to either reduce virus load and/or the cytokine storm
in patients with severe COVID-19 infections. It has been found
that BTK activation and IL-6 production is increased in COVID-
19 patients and the effects of acalabrutinib are currently being
evaluated in these patients (17). Roschewski et al. (17) showed
that some severe COVID-19 patients receiving acalabrutinib
had improved oxygenation and reduced CRP and plasma IL-6,
suggesting that BTK inhibitors could be repurposed for diseases
involving excessive inflammation.
Although we have proposed that the inhibition of BTK
is the key driver of the observed beneficial effects of BTK
inhibitors in sepsis, it is possible that some of the well-known
off-target effects of these compounds account for or, at least,
contribute to the beneficial effects observed (14). For instance, we
identified that both ibrutinib and acalabrutinib strongly inhibit
five different kinases: BTK, Bmx, ErbB4, RIPK2, and TEC. Our
discovery that acalabrutinib and ibrutinib reduce inflammation
and organ dysfunction in sepsis has triggered three important
questions: (1) Does inhibition of BTK activity alone account
for the observed beneficial effects? And (2) Does inhibition of
systemic inflammation reduce the host response to infection
and ultimately cause increased harm? (3) What effect does BTK
inactivation have on the metabolomic profile of septic mice?
Interest in metabolomic profiling is growing, as the metabolome
is the result of expression and function of a multitude of proteins
and, hence, has been suggested to be a sensitive readout of
drug responses (18, 19). The present study was designed to
address these questions by inducing polymicrobial sepsis in
mice with X-linked immunodeficiency (Xid). Xid mice have a
missense mutation within the BTK gene [arginine to cysteine
at position 28 (R28C)] in the N-terminally located pleckstrin
homology domain, resulting in expression of a BTK protein that
is functionally inactive (20, 21). Having developed a model of
sepsis in Xid mice (and wild-type mice, CBA background), we
have investigated the impact of impaired BTK function on organ
dysfunction, systemic inflammation (cytokine storm), changes in
plasma metabolites, and bacterial clearance.
METHODS
Ethical Statement
The Animal Welfare Ethics Review Boards of Queen Mary
University of London and The Dunn School of Pathology in the
University of Oxford approved all experiments in accordance
with the Home Office guidance on the operation of Animals
(Scientific Procedures Act 1986) published by Her Majesty’s
Stationery Office and the Guide for the Care and Use of
Laboratory Animals of the National Research Council. Work
was conducted under U.K. Home Office project license number
PCF29685 and P144E44F2.
Mice
This study was carried out on twenty-three 10 week-old, male
CBA mice (Charles River Laboratories UK Ltd., Kent, UK)
and twenty-one 10 week-old, male CBA/CaHN-Btkxid/J (Xid)
mice (from Jackson laboratory), weighing 25–30 g and kept
under standard laboratory conditions. Six mice were housed
together (in each cage) with access to a chow diet and water
ad libitum. They were subjected to a 12 h light and dark cycle
with a temperature maintained at 19–23◦C. Group sizes for each
experiment were calculated following power calculations based
on previous studies (14).
Polymicrobial Sepsis
Cecal ligation and puncture (CLP) was performed in 10 week-
old male CBA (wild type) or Xid mice as previously described
(14, 22). Mice were randomly assigned to undergo CLP or sham-
operated surgery, the surgeon was blinded to the genotype of
the mouse. Briefly, mice were anesthetised with isoflurane (2%
delivered in O2) and the cecum was fully ligated below the
ileocecal valve. A double puncture was made with a 18G needle
into the cecum and a small amount of feces was squeezed out
after which the cecum was returned to its anatomical position,
then the laparotomy was closed. All animals received fluids (5
ml/kg saline into abdomen before closure and 10 ml/kg saline
s.c., immediately after surgery), antibiotics (Imipenem/Cilastatin;
20mg/kg dissolved in 7.5ml/kg of saline s.c.), and analgesics
(buprenorphine; 0.05mg/kg i.p.) at 6 and 18 h after surgery.
Sham-operatedmice underwent the same procedure, but without
CLP. At 1 h after CLP, WT or Xid mice received 30 mg/kg
ibrutinib (Selleck Chemicals) intravenously.
A clinical score for monitoring the health of experimental
mice was used to evaluate the symptoms consistent with murine
sepsis. The maximum score of six comprised the presence of
the following signs: lethargy, piloerection, tremors, periorbital
exudates, respiratory distress, and diarrhea. Mice with a clinical
score >3 were defined as exhibiting severe sepsis, against a
moderate sepsis for a score ≤3. Animals were culled at 24 h after
the onset of sepsis (CLP).
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Assessment of Cardiac Function in vivo
At 24 h post CLP, mice were anesthetised (0.5–2% isoflurane
in O2); body temperature was maintained at 37
◦C and heart
rate was maintained at 450 bpm. Then, cardiac function was
assessed by M-mode and B-mode echocardiography using
the VisualSonics Vevo 3100 echocardiographic system and a
MX550D transducer. The following parameters were measured:
left ventricular ejection fraction, fractional shortening, fractional
area change, cardiac output, stroke volume, and myocardial
performance index, as described previously (14).
Kidney Dysfunction and Hepatocellular
Injury
After 24 h, mice were sacrificed by terminal cardiac puncture,
where terminal blood samples were immediately decanted into
1.3ml serum gel tubes (Sarstedt, Nürnbrecht, Germany). Blood
was allowed to coagulate for at least 10min at room temperature,
then samples were centrifuged at 9,000 rpm for 3min to separate
the serum. Then 100 µl of serum was snap frozen in liquid
nitrogen and sent to an independent veterinary testing laboratory
(MRC Harwell Institute, Oxford, UK) to evaluate the following
biomarkers in a blinded fashion: Urea and creatinine (as markers
of renal dysfunction), alanine aminotransferase (ALT), aspartate
transaminase (AST) (markers of hepatocellular injury), and
lactate dehydrogenase (LDH) (marker of cell injury).
Quantification of Immune Cells After
Peritoneal Lavage
Peritoneal lavage exudate was collected by injecting 5ml of
2mM of EDTA in PBS into the peritoneal cavity. After gentle
massaging, ∼4ml of exudate was removed with an 18G needle.
Cells were washed in FACS buffer (0.05 % BSA, 2mM EDTA in
PBS pH 7.4) and then blocked using anti-CD16/32 (Biolegend)
for 10min at 4◦C. Peritoneal cells were analyzed using anti-
CD45 (clone 30-F11; BioLegend), anti-CD11b (clone M1/70;
BioLegend), anti-F4/80 (clone BM8; BioLegend), anti-Ly6G
(clone 1A8; BioLegend), anti-CD206 (clone C068C2; BioLegend),
and anti-MHCII (clone. M5/114.15.2; BioLegend) antibodies.
Absolute cell count was calculated by the addition of counting
beads (BioLegend). Data were acquired using BD LSR II Fortessa
(Becton Dickinson) and analyzed using FlowJo analysis software
(version 10.6, Treestar Inc.). The gating strategy is depicted in
Figure S1.
Cytokine Analysis
The principle of multiplex flow immunoassay technology has
been reviewed previously (23, 24). Cytokines, chemokines, and
a growth factor were determined in serum by Bio-Plex Pro
Mouse Chemokine 31-Plex panel assay (Bio-Rad, Kabelsketal,
Germany). The cytokines IL-1ß, −2, −4, −6, −10, −16, CCL1,
−2,−3,−4,−5,−7,−11,−12,−17,−19,−20,−22,−24,−27,
IFN-γ, TNF-α and the chemokines CX3CL1, CXCL1, −2, −5,
−10, −11, −12, −13, −16, and the growth factor GM-CSF were
measured according to the manufacturer’s instructions.
Bacteria Counting
Accurate evaluation of the number of bacteria in peritoneal
lavage fluid and blood samples was performed by flow
cytometry using the SYTO BC bacteria counting kit (Thermo
Fischer Scientific).
Phagocytic Ability
Peritoneal lavage exudate containing neutrophils and
macrophages was obtained 24 h after CLP as described above.
pHrodoTM red E. Coli bioparticlesTM (Thermo Fischer Scientific)
were resuspended in live cell imagining solution (BioLegend) at
10 mg/ml and 10 µL of bioparticles were opsonised with 20 µL
of fresh serum for 1 h at 37◦C under gentle agitation, after which
they were washed and resuspended in 10µL of live cell imagining
solution. 1 × 106 cells of peritoneal exudate were collected by
centrifugation (300 g × 5min) and resuspended in 890 µL of
live cell imaging solution, after which 100 µl of fresh serum
and 10 µL of optimized bioparticles were added and incubated
for 45min at 37◦C under gentle agitation in the dark. Cells
were washed and then blocked using anti-CD16/32 (Biolegend)
for 10min at 4◦C followed by staining with surface markers
anti-CD11b (clone M1/70; BioLegend), anti-Ly6G (clone
1A8; BioLegend), and anti-F4/80 (clone BM8; BioLegend) for
30min at 4◦C. 10,000 CD11b+ cells were collected by Amnis R©
ImageStream R©X Mk II Imaging Flow Cytometer (Luminex) at a
magnification of x40 and analyzed by IDEAS software for each
experimental sample. Neutrophils were identified as (CD11b+,
Ly6G+, F4/80−) and macrophages were identified as (CD11b+,
Ly6G−, F4/80+). This equated to ∼7,000 neutrophils and 2,000
macrophages for bothWT and Xidmice to undergo phagocytosis
analysis via IDEAS software. For WT mice the average number
of cells positive with pHrodo E. coli BioParticles were 4,200
neutrophils and 1,200 macrophages. For Xid mice the average
number of cells positive with pHrodo E. coli BioParticles were
neutrophils 5,600 and 1,200 macrophages.
Western Blots
Immunoblot analyses of cardiac tissue samples were carried out
using a semi-quantitative western blotting analysis. The antibody
used were: 1:1,000 rabbit anti-Ser176/180-IKKα/β, 1:1,000 rabbit
anti-total IKKα/β, mouse anti-Ser32/36-IκBα, mouse anti-total
IκBα, rabbit anti-Tyr223-BTK, rabbit anti-total BTK, rabbit anti-
Tyr1217 PLCγ, rabbit anti-total PLCγ (from Cell Signaling),
1:5,000 rabbit anti NLRP3 inflammasome (from Abcam), mouse
anti-caspase 1 (p20) (from Adipogen). The apex of the heart
was taken and homogenized. Proteins were then extracted as
previously described (25) and concentrations were quantified by
bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific
Rockford, IL). Proteins were separated by 8% sodium dodecyl
sulfate (SDS)-PAGE and transferred to polyvinylidene fluoride
membranes. Membranes were blocked in 10% milk solution
with TBS-Tween and then incubated with the primary antibody
overnight at 4◦C. The next day the secondary antibody was
added for 30min at room temperature and visualized using the
ECL detection system. Tubulin was used as loading control. The
immunoreactive bands were analyzed by the Bio-Rad Image Lab
SoftwareTM 6.0.1 and results were normalized to the sham bands.
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BTK Gene Expression in Whole Human
Blood
Original data was obtained from the gene expression omnibus
under dataset number GDS4971 which was published by Parnell
et al. (26). RNA isolated from whole-blood samples of survivors
(n = 26) and non-survivors (n = 9) of sepsis as well as healthy
participants (n = 18) over the course of 5 days was assayed on
the Illumina HT-12 gene expression microarray consisting of
48,804 probes. The dataset was analyzed for expression of BTK
gene in these three groups. The figure was generated using R
software (ver 4.0.2), gene expression is quantile normalization
and log transformation of the data was applied. Significance was
determined by a one-way ANOVA followed by a Bonferroni
post hoc-test.
Metabolomic Analysis
Metabolites were analyzed by liquid chromatography coupled
to triple quadrupole mass spectrometry (LC-MS/MS) using
an ultra-high-performance liquid chromatography (UHPLC)
system (Nexera LC-40 series) and the triple quadrupole mass
spectrometer LCMS-8050, both from Shimadzu Deutschland
GmbH (Duisburg, Germany). Samples were analyzed with
a method for sphingosine-1-phosphate and sphingosine
and the supplied method packages “primary metabolites,”
“phospholipids,” and “lipid mediators” according to the
manufacturer’s protocols (Shimadzu Deutschland GmbH,
Duisburg, Germany) with the following modifications: 20
µL of serum sample were precipitated by addition of 200
µL of methanol (LCMS-grade) in vials. Prior to processing,
the methanol was spiked with internal standard (IS) solution
in a final concentration of 45.45 nM. The supernatant was
taken for analysis after 4 days of incubation at −80◦C and
subsequent centrifugation at 14,000 rcf for 10min at 4◦C.
Primary metabolites were analyzed using the HPLC Column
Discovery R© HS F5, 3µm, 150 × 2.1mm from Sigma-Aldrich
Chemie GmbH (Munich, Germany). For phospholipids and
lipid mediators, the 2.1 × 150mm 2.6µm particle size C8
Kinetex LC Column (Phenomenex Inc., Torrance, USA)
was used. Sphingosine-1-phosphate and sphingosine were
separated using a MultoHigh 100 RP 18-3µ 60 × 2mm column
(Chromatographie Service GmbH, Langerwehe, Germany)
with intermittent runs for equilibration. Mass spectrometric
detection was performed by multiple reactions monitoring
(MRM) after injection of 10 µl sample, unless stated otherwise.
Further information on HPLC programs and solvents (Table S1),
LCMS-8050 settings (Table S2), and recorded mass transitions
of identified significantly changed analytes (Tables S3–S6)
are listed in the Supplement. Metabolome primary data were
analyzed and further processed with LabSolutions 5.91 and
LabSolutions Insight 3.10 (Shimadzu Deutschland GmbH,
Duisburg, Germany).
Statistics
Statistical differences were determined using a one-way ANOVA,
followed by Bonferroni post hoc-test or unpaired Student’s t-test
as appropriate (GraphPad Prism 8.0; significant when P < 0.05).
Results are expressed as mean± SEM of n observations, where n
represents the number of animals studied.
Metabolome data were determined by calculating area ratios
for each analyte by dividing peak area of each analyte by
peak area of the related IS. Data analysis for metabolome
data was performed as follows: Readings below detection level
were set to half of detection level for each analyte separately.
Metabolome data was log2 transformed and normalized by
subtracting median metabolite abundance per sample from all
abundances of each sample. Normalization was carried out
separately for primary metabolites, phospholipids, and lipid
mediators. Z scores were calculated using mean and standard
deviation of all samples. Contrasts were analyzed pairwise
between selected sample groups by unpaired t-tests. P-values
were Benjamini Hochberg adjusted (27). Analytes with adjusted
P-values below 0.05 were considered significantly different. For
a first exploratory overview a principal component analysis
(PCA) was carried out using the normalized and scaled
metabolome data. Data analysis was carried out using R version
3.4.4 (28).
RESULTS
Xid Mice Have 100% Predicted Survival
Rate
When compared to sham-operated mice, WT mice subjected
to cecal ligation and puncture (CLP) showed clinical signs of
severe sepsis (80%; score >3). In contrast, all Xid mice subjected
to CLP had a score of ≤3 indicating only moderate sepsis
(Figure 1A). All mice in the WT-CLP group which received
ibrutinib had a score of ≤3 indicating moderate sepsis and all
mice in the Xid-CLP + ibrutinib group had a score ≤3. When
compared to sham-operated mice, WT mice subjected to CLP
experienced hypothermia (a rectal temperature of<30◦C) at 24 h
after the onset of CLP, whereas the rectal temperature of Xid-
CLP, WT-CLP + ibrutinib and Xid-CLP + ibrutinib remained
at 37◦C (Figure 1B). A reduction in temperature to <30◦C or
a change of 5◦C over time in each animal has been reported to
predict death in mice with CLP (29). As mortality of animals
is not an acceptable routine endpoint in the UK, we used the
reduction in rectal temperature <30◦C as a surrogate marker
for mortality. Using this surrogate marker, we would predict
the mortality of WT-CLP mice to be 90% (confirming that our
model is a model of severe sepsis), while the predicted mortality
of Xid-CLP mice would be 0% (e.g., 100% predicted survival;
Figure 1C). WT-CLP mice receiving ibrutinib had a predicted
mortality of 15%, whereas Xid-CLP mice receiving ibrutinib
had a predicted mortality of 0%. When compared to sham-
operated mice, WT mice subjected to CLP showed a decrease
in heart rate, whereas the heart rate of Xid-CLP remained
similar to that of sham-operated animals (Figure 1D). When
compared to WT-CLP mice, the administration of ibrutinib 1 h
after CLP attenuated the decline in heart rate in WT mice.
Mice in the Xid-CLP + ibrutinib group had a similar heart
rate to mice in the Xid-CLP group. Xid-CLP mice receiving
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FIGURE 1 | Xid mice are protected from sepsis-induced multiple organ failure. WT and Xid mice were randomly selected to undergo sham or CLP surgery, 1 h later
ibrutinib (30 mg/kg) was administered intravenously. At 24 h after CLP, cardiac function was assessed by echocardiography and parameters of renal and liver function
were assessed in serum. (A) Severity Score 24 h after CLP. (B) Temperature 24 h after CLP (◦C). (C) Predicted percentage of survival (%). (D) Heart rate 24 h after CLP
(Continued)
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FIGURE 1 | (bmp). (E) Representative m-mode images. (F) Ejection Fraction (%). (G) Fractional shortening (%). (H) Fractional area change (%). (I) Cardiac output
(ml/min). (J) Stroke volume (µL). (K) Myocardial performance index (NFT). (L) Urea (mmol/L). (M) Creatinine (µmol/L). (N) Lactate dehydrogenase (U/L). (O) ATL (U/L).
(P) AST (U/L). The following groups were studied WT sham (n = 5), Xid sham (n = 5), WT-CLP (n = 10), Xid-CLP (n = 10), WT-CLP + ibrutinib (n = 8), and Xid-CLP +
ibrutinib (n = 6). Data are expressed as mean ± SEM and analyzed by one-way ANOVA with a Bonferroni post hoc-test. *P < 0.05, **P < 0.01, ***P < 0.001, and
****P < 0.0001 vs. WT-CLP.
ibrutinib had a higher heart rate than WT-CLP mice treated
with ibrutinib.
Xid Mice Are Protected From
Sepsis-Induced Cardiac Dysfunction
Cardiac function was assessed in vivo by echocardiography.
Figure 1E shows representative M-mode images in the short axis
in sham-operated mice, CLP mice, and CLP + ibrutinib mice of
both genotypes. When compared to sham-operated mice, WT
mice subjected to CLP showed a reduction in ejection fraction
(EF), fractional shortening (FS), fractional area change (FAC),
cardiac output (CO), stroke volume (SV), and an increase in
myocardial performance index (MPI), indicating severe global,
systolic cardiac dysfunction. In contrast, Xid mice subjected
to CLP had only a very minor cardiac dysfunction and all
indices of cardiac performance (EF, FS, FAC, CO, SV, and MPI)
were significantly improved from those measured in WT-CLP
(Figures 1F–K). Thus, the degree of cardiac dysfunction caused
by CLP in Xid mice is significantly reduced when compared
to that observed in WT-mice. When compared to WT-CLP
mice (CBA background) treatment of WT-mice with ibrutinib
1 h after CLP attenuated the sepsis-induced cardiac dysfunction.
In contrast, administration of ibrutinib to Xid-CLP mice had
no effect on cardiac function (Figures 1F–K), indicating that
the addition of ibrutinib in Xid mice with CLP results in no
beneficial or deleterious effects due to off target actions of
the drug.
Xid Mice Are Protected From
Sepsis-Induced Kidney Dysfunction and
Hepatocellular Injury
Kidney dysfunction and hepatocellular injury was assessed by
measuring serum creatinine, urea, ALT, AST, and LDH. When
compared to sham-operated mice, WT mice subjected to CLP
had significant renal dysfunction (rise in urea and creatinine),
hepatocellular injury (rise in ALT and AST) and cell injury
(rise in LDH). In contrast, in Xid mice subjected to CLP, the
degree of kidney dysfunction, hepatocellular injury and cell
injury was significantly reduced when compared to WT-CLP
mice (Figures 1L–P). When compared to WT-CLP, treatment
of WT-CLP mice with ibrutinib (1 h after CLP) significantly
attenuated the rise of plasma/serum urea, creatinine, ALT, AST,
and LDH. In contrast, administration of ibrutinib in Xid-CLP
mice had no significant effect on organ dysfunction (as this was
prevented in Xid-mice). No significant difference was observed
between WT-CLP + ibrutinib and Xid-CLP + ibrutinib for any
of the parameters of organ dysfunction measured.
Xid Mice Do Not Present With Systemic
Inflammation After Polymicrobial Sepsis
Using a multiplex array, we analyzed 31 cytokines and
chemokines in the serum of all animals. When compared to
sham-operated mice, WT mice subjected to CLP sepsis showed
a significant increase in the serum levels of pro-inflammatory
cytokines TNF-α, IL-6, and IL-1β, the anti-inflammatory
cytokine IL-10, neutrophils chemoattractant chemokines
(KC & ENA-78), monocyte chemoattractant chemokines
(MCP-1, MIP-1α, and MIP-1β) and G-CSF. In contrast,
the levels of these cytokines and chemokines in the serum
of Xid-CLP were significantly reduced when compared to
WT-CLP mice (Figures 2A–J). When compared to WT-CLP,
treatment of WT-CLP mice with ibrutinib (1 h after CLP)
significantly attenuated the rise in cytokines and chemokines.
In contrast, administration of ibrutinib in Xid-CLP-mice
had no significant effect on the production of cytokines
and chemokines (as this was prevented in Xid-mice). No
significant difference was observed between WT-CLP +
ibrutinib and Xid-CLP + ibrutinib for any cytokines and
chemokines. The alterations of a further 21 cytokines and
chemokines can be seen in Figure 2K and absolute values in
Table S7.
Xid Mice Have Fewer Infiltrating Immune
Cells in the Peritoneum and Enhanced
Polarization to M2 Macrophages in Sepsis
We also evaluated the cell composition and phenotype in
the peritoneal exudates of all animals by flow cytometry
gating strategy seen in Figure S1. When compared to sham-
operated mice, WT mice subjected to CLP showed a significant
increase in neutrophils and macrophages into the peritoneum.
In contrast, Xid-CLP mice exhibited a significant reduction
in the number of infiltrating neutrophils and macrophages
when compared to WT-CLP mice (Figures 3A–C). Upon further
analysis of the subsets of macrophages, we found that the
macrophages obtained fromWT-CLP mice are predominately of
the pro-inflammatory M1 phenotype (60% M1 and 40% M2),
while the macrophages of Xid-CLP are of the pro-resolving
(anti-inflammatory) M2 phenotype (40% M1 and 60% M2)
(Figures 3D,E).
Xid Mice Have Fewer Bacteria in
Peritoneum and Blood Due to Increased
Phagocytosis in Sepsis
In order to determine the mechanism that accounts for the
improved outcome of BTK deficient mice, we investigated
bacterial clearance in vivo in WT and Xid-mice at 24 h after
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FIGURE 2 | Xid mice do not present with systemic inflammation after polymicrobial sepsis. Mice underwent sham or CLP surgery, 24 h later cytokines and
chemokines were assessed in serum. (A) TNF-α serum concentration (pg/ml). (B) IL-6 serum concentration (pg/ml). (C) IL-1β serum concentration (pg/ml). (D) IL-10
serum concentration (pg/ml). (E) KC/CXCL1 serum concentration (pg/ml). (F) ENA-78/CXCL5 serum concentration (pg/ml). (G) GM-CSF serum concentration (pg/ml).
(H) MCP-1/CCL2 serum concentration (pg/ml). (I) MIP-1α/CCL3 serum concentration (pg/ml). (J) MIP-1β/CCL4 serum concentration (pg/ml). (K) Heat-map of 31
cytokines/chemokines serum concentration (pg/ml). The following groups were studied WT sham (n = 5), Xid sham (n = 5), WT-CLP (n = 10), Xid-CLP (n = 10),
WT-CLP + ibrutinib (n = 8), and Xid-CLP + ibrutinib (n = 6). Data are expressed as mean ± SEM and analyzed by one-way ANOVA with a Bonferroni post hoc-test.
*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 vs. WT-CLP.
the onset of CLP, as the survival of sepsis is dependent
on the ability to clear bacteria. When compared to sham-
operated mice, WT mice subjected to CLP exhibited elevated
peritoneal and blood bacteria counts (Figures 4A–D).
However, Xid-CLP mice had significantly fewer bacteria
in the peritoneal cavity and blood than WT-CLP mice,
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FIGURE 3 | Xid mice have fewer infiltrating immune cells in the peritoneum and enhanced polarization to M2 macrophages. Mice underwent sham or CLP surgery,
24 h later peritoneal lavage fluid was analyzed. (A) Scattergrams illustrating macrophage (identified as F4/80+Ly6G− ) and neutrophils (identified as F4/80−Ly6G+). (B)
Peritoneal neutrophil (F4/80−Ly6G+ ) cell count per ml. (C) Peritoneal macrophage (F4/80+Ly6G−) cell count per ml. (D) Contour plot illustrating percentage of M1 and
M2 macrophages in WT and Xid mice, M1 identified as MHCII+CD206− and M2 identified as MHCII+CD206+. (E) Percentage of M1 and M2 macrophages in WT
mice and Xid mice (%). The following groups were studied WT sham (n = 5), Xid sham (n = 5), WT-CLP (n = 10), and Xid-CLP (n = 10). Data are expressed as mean
± SEM and analyzed by one-way ANOVA with a Bonferroni post hoc-test. *P < 0.05, ***P < 0.001, and ****P < 0.0001 vs. WT-CLP.
showing that Xid-mice clear bacteria more efficiently than
WT mice.
Clearance of bacteria is secondary to phagocytosis of bacteria
in neutrophils and macrophages. Xid mice subjected to CLP
presented with a reduced number of infiltrating immune cells,
but also reduced bacterial counts at 24 h post CLP. This raises
the question as to how fewer infiltrating immune cells are able
to clear more bacteria? To address this question, we investigated
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FIGURE 4 | Xid mice result in enhanced bacterial clearance in peritoneum and blood due to increased phagocytosis in sepsis. Mice underwent sham or CLP surgery,
24 h later peritoneal lavage fluid and blood were analyzed. Macrophages identified as (CD11b+, F4/80+, and Ly6G− ) and neutrophils identified as (CD11b+, F4/80−,
and Ly6G+). (A) Representative images of peritoneal bacteria cell count. (B) Peritoneum bacteria cell count per ml. (C) Representative images of blood bacteria cell
count. (D) Blood bacteria cell count per ml. (E) Representative images of WT-CLP macrophages phagocytosis on the imagestream. (F) Representative images of
Xid-CLP macrophages phagocytosis on the imagestream. (G) Percentage of phagocytosing macrophages (%). (H) Average number of pHrodo red E. coli BioParticles
within macrophages. (I) Representative images of WT-CLP neutrophil phagocytosis on the imagestream. (J) Representative images of Xid-CLP neutrophil
phagocytosis on the imagestream. (K) Percentage of phagocytosing neutrophils (%). (L) Average number of pHrodo red E. coli BioParticles within neutrophils. The
following groups were studied WT sham (n = 5), Xid sham (n = 5,) WT-CLP (n = 10), and Xid-CLP (n = 10). Data are expressed as mean ± SEM and analyzed by
one-way ANOVA with a Bonferroni post hoc-test or a two-tailed Students t-test as appropriate. **P < 0.01, ***P < 0.001, and ****P < 0.0001 vs. WT-CLP.
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FIGURE 5 | BTK, NF-κB, and NLRP3 inflammasome are not activated in Xid mice after polymicrobial sepsis. Mice underwent sham-operated or CLP surgery and
24 h later signaling events in the cardiac tissue were assessed. Densitometric analysis of the bands is expressed as relative optical density (O.D.) of (A)
phosphorylation of BTK at Tyr223 corrected for the corresponding total BTK and normalized using the related sham bands. (B) Phosphorylation of PLCγ at Tyr1217
(Continued)
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FIGURE 5 | corrected for the corresponding total PLCγ and normalized using the related sham bands. (C) Phosphorylation of IKKα/β at Ser176/180 corrected for the
corresponding total IKKα/β and normalized using the sham related bands. (D) Phosphorylation of IκBα at Ser32/36 corrected for the corresponding total IκBα and
normalized using the related sham band. (E) NLRP3 activation, corrected against tubulin and normalized using the sham related bands. (F) Pro-caspase-1 against
activated caspase-1 and normalized using the sham related bands. The following groups were studied WT sham (n = 4), Xid sham (n = 4), WT-CLP (n = 4), and
Xid-CLP (n = 4). Data are expressed as mean ± SEM and analyzed by one-way ANOVA with a Bonferroni post hoc-test. ***P < 0.001 and ****P < 0.0001 vs. WT-CLP.
whether Xid neutrophils and macrophages have increased
phagocytic ability in vivo. We found that the percentage of
neutrophils and macrophages, which are phagocytosing bacteria,
are similar in WT-CLP and Xid-CLP mice. However, neutrophils
and macrophages of Xid-CLP mice contain more bacteria per
immune cell than WT-CLP mice, showing a 100% increase
in phagocytic ability of both neutrophils and macrophages
(Figures 4E–L). Collectively, this data clearly demonstrates that
Xid mice with a deficiency in BTK show enhanced phagocytosis
in vivo resulting in improved clearance of bacteria during a
septic episode.
BTK, NF-κB, and NLRP3 Inflammasome
Are Not Activated in Xid Mice After
Polymicrobial Sepsis
To understand the signaling mechanism associated with the
observed cardiac dysfunction in CLP-sepsis, we investigated
the effect of BTK deficiency in Xid mice on the activation
of key signaling pathways of inflammation: BTK, NF-κB, and
NLRP3 inflammasome activation (Figure 5). When compared
to sham-operated mice, WT mice subjected to CLP showed
an increase of BTK activation as demonstrated by significant
increases in the phosphorylation of cardiac BTK at Tyr223
and the phosphorylation of PLCγ at Tyr1217. No activation
of BTK was detected in Xid mice, even after CLP injury
and the phosphorylation of cardiac BTK at Tyr223 and the
phosphorylation of PLCγ at Tyr1217 in Xid-CLP mice were
similar to that of sham-operated animals (Figures 5A,B).
NF-κB activation plays a key role in the pathophysiology of
sepsis. When compared to sham-operated mice, WT-CLP mice
exhibit a significant increase inNF-κB activation as demonstrated
by significant increases in the phosphorylation of IKKα/β at
Ser176/180 and the phosphorylation of IκBα at Ser32/36. When
compared to WT-CLP mice, Xid-CLP mice the phosphorylation
of IKKα/β at Ser176/180 and IκBα at Ser32/36 was significantly
reduced, indicating that the degree of activation of NF-κB caused
by sepsis in the heart was significantly lower in Xid-mice than in
WT-mice (Figures 5C,D).
When compared to sham-operated mice, WT mice subjected
to CLP showed an increase in the activation of the NLRP3
inflammasome, demonstrated by an increase in the expression
of the NLRP3 inflammasome and cleavage of pro-caspase-
1 to caspase-1 in the heart (Figures 5E,F) as well as an
increase the production of IL-1β in serum (Figure 2C). In
contrast, Xid-CLP mice showed reduced activation of NLRP3
inflammasome as demonstrated by a decrease in the expression of
the NLRP3 inflammasome, cleavage of pro-caspase-1 to caspase-
1 (Figures 5E,F) and IL-1β when compared to WT-CLP mice
(Figure 2C).
FIGURE 6 | Principal component analysis (PCA). Principal component analysis
(PCA) of the normalized and scaled metabolome data. Plot shows first two
principal components (PC), which account for almost half of the total variance
in the data set. Variance between replicates is far less than between different
experimental conditions. Contrasts between main experimental conditions are
visible in the shown PCs. Each dot represents a sample and each color
represents a mice group.
Xid Mice Show Lower Levels of
Sepsis-Dysregulated Metabolites
Using a targetedmetabolomic approach, we detected 240 analytes
in murine plasma. A two-dimensional principal component
analysis (PCA) of all detected analytes (Figure 6), revealed a
clear distinction between the two sham-operated mice groups
(WT sham and Xid sham), the WT-CLP mice group and the
three treated and/orXid CLP-inducedmice groups (Xid CLP,WT
CLP + Ibrutinib, and Xid CLP + Ibrutinib). The first principal
component explained about 36% of total variation among the
six mice groups and separated the sham-operated mice from
the CLP-induced mice groups. The second principal component
explained about 13% of total variation of all metabolites and
achieved the same effect as PC2, but further it separated the
CLP-induced WT mice group from the three mice groups Xid
CLP, WT CLP + ibrutinib, and Xid CLP + ibrutinib. Significant
changes in analytes were identified and analyzed via hierarchical
clustered z score heatmaps and their significant log2-fold changes
of selected group comparisons were shown in log2-fold change
heatmaps (Figures S2–S5). The heatmaps illustrate 55 significant
primary metabolites (Figure S2), 138 significant phospholipids
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FIGURE 7 | Heatmap of significant restored metabolites in the groups XID CLP, WT CLP + Ibrutinib, and XID CLP + Ibrutinib. (A) Hierarchical clustered z score
heatmaps showed significantly changed analytes and (B) log2-fold change heatmaps showed their significant log2-fold changes for selected groupwise comparisons.
The heatmap shows analytes which, compared to the WT CLP group (n = 10), restored in all three groups [Xid-CLP (n = 10), WT-CLP + ibrutinib (n = 8), and
Xid-CLP + ibrutinib (n = 6)] to the level of the two sham groups [WT Sham (n = 5), Xid Sham (n = 5)]. Each column in a z score heatmap represented the mean value
of all animals in a group, each column in a log2-fold change heatmap represented a groupwise comparison and each row defined an analyte. Analytes were
hierarchically clustered using Ward’s minimum variance method (76) and an euclidian distance between log2-fold changes. Dendrograms provide information about
distances between clusters. AA, arachidonic acid; AEA, arachidonoylethanolamide; DHA, docosahexaenoic acid; DOPA, dihydroxyphenylalanine; EPA,
eicosapentaenoic acid; LPE, lysophosphatidylethanolamine; LPG, lysophosphatidylglycerol; LPS, lysophosphatidylserine; lyso-PAF, lyso-platelet activating factor;
OEA, oleoylethanolamine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine; TDCA, taurodeoxycholic acid.
and their derivatives (Figures S3,S4), and 6 significant lipid
mediators (Figure S5).
Figure 7 shows a sorting of 24 analytes that were significantly
restored in the three mice groups Xid-CLP, WT-CLP +
ibrutinib, and Xid-CLP + ibrutinib to the initial levels of
both sham-operated groups compared to the WT-CLP mice
group. The ibrutinib treatment or the BTK inactivation or
the combination of both restored 7 significant decreased and
17 significant increased analytes in CLP-induced WT-mice.
The decreased analytes belonged predominantly to the lipid
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mediator’s docosahexaenoic acid (DHA), eicosapentaenoic
acid (EPA), lyso-platelet activating factor (lyso-PAF), and
oleoylethanolamine (OEA). The bile acid taurodeoxycholic
acid (TDCA), the phosphatidylinositol (PI) (34:2) and
the primary metabolite niacinamide were also reduced.
The increased analytes included five primary metabolites
(dihydroxyphenylalanine (DOPA), creatine, carnosine,
nicotinic acid, cytosine), four lysophosphatidylserines, five
phosphatidylserines, one lysophosphatidylethanolamine, one
lysophaphatidylglycerol and one phosphytidylethanolamine.
Sorting by analytes that were only significantly restored
in Xid-CLP (Figure S6) showed five analytes. One analyte
was increased, the primary metabolite kynurenine, and
four analytes were decreased in the WT-CLP group and
this included the primary metabolite uridine and one the
phospholipids phosphatidylserine, phosphatidylethanolamine,
and phosphatidylinositol. Twenty-three analytes showed
the sorting by significantly restored analytes in the mice
groups Xid CLP and Xid CLP + Ibrutinib (Figure S7). The
levels of 10 analytes (cGMP, creatinine, ursodeoxycholic
acid (UDCA), deoxycholic acid (DCA), adenine, one
lysophosphatidylserine, one lysophosphatidylglycerol, three
lysophosphatidylethanolamines) were upregulated and 13
analytes (one sphingomyelin, six phosphatidylcholines,
three phosphatidylethanolamines, two phosphatidylserines,
one phosphatidylinositol) were downregulated in CLP-
induced wildtype mice. Analytes that were only restored
in the mice group WT-CLP + ibrutinib could not
be determined. The heatmap with analytes that were
significantly restored in the mice groups WT-CLP +
ibrutinib and Xid-CLP + ibrutinib (Figure S8) showed
one increased primary metabolite (cholesterol) and three
decreased phospholipids (two phosphatidylserines and one
lysophosphatidylserine).
Expression of BTK Is Increased in Whole
Human Blood of Septic Non-survivors
Parnell et al. (26) collected whole blood of patients confirmed
with sepsis (and healthy participants) over a 5 day time course
with the first day of collection being within the initial 24 h
of admission to the ICU. RNA was extracted from whole
blood and gene expression was analyzed by microarray. Three
groups were collected, healthy participants, septic survivors
and septic non-survivors. Dataset is available on the gene
expression omnibus under GDS4791. We reanalysed this dataset
for BTK expression in these three groups and found that at
day 1 there is no significant differences in gene expression
between healthy, septic survivors, and septic non-survivors
(Figures 8A,B). However, over the course of 5 days BTK
expression increases in septic non-survivors and a significant
difference between non-survivors and healthy participants as well
as a significant difference between non-survivors and survivors
is observed at day 5 (Figure 8C). There was no significant
difference in BTK expression between septic survivors and
healthy volunteers (Figures 8A–C).
DISCUSSION
Sepsis is the overwhelming host response to infection (bacterial,
fungal, or viral) leading to shock and multiple organ dysfunction.
We have previously reported that BTK inhibitors (ibrutinib,
acalabrutinib) significantly attenuate sepsis-induced cardiac
dysfunction and reduced inflammatory cytokine production,
but BTK inhibitors have many off target effects (14). In the
present study we investigated whether the beneficial effects are
exclusively due to inhibition of BTK and how a reduction in
systemic inflammation due to BTK loss of function mutation
affects bacterial clearance in vivo. We addressed these questions
by conducting a model of polymicrobial sepsis in Xid mice
(which have a missense mutation in the BTK gene, resulting
in BTK to be functionally impaired). We report here for the
first time that Xid mice are protected from sepsis-induced
multiple organ dysfunction (cardiac, renal, and hepatocellular)
due to increased bacterial clearance and suppression of
systemic inflammation (cytokine storm) (please see Figure 9 for
schematic diagram of the role of BTK in the pathophysiology
of sepsis).
BTK Inactivation Prevents Sepsis-Induced
Multiple Organ Dysfunction
Sepsis results in multiple organ failure including cardiac
dysfunction, renal dysfunction and hepatocellular injury. We
report here for the first time that Xid mice subjected to
sepsis are protected from developing cardiac dysfunction,
hepatocellular injury, and renal dysfunction. Most notably,
ibrutinib significantly reduced sepsis-induced multiple organ
failure in WT-mice but had no further beneficial effect in Xid-
mice subjected to CLP-indicating that the observed beneficial
effect of ibrutinib in WT-mice can solely be explained by
inhibition of BTK-activity. We have previously reported that
inhibition of BTK by ibrutinib or acalabrutinib attenuate sepsis-
induced cardiac and renal dysfunction in C57Bl/6 mice (14) and
additionally we have now shown that delayed administration
of ibrutinib in WT-CLP (CBA background) also attenuates
sepsis-induced cardiac dysfunction, renal dysfunction, and
hepatocellular injury, confirming that BTK inhibitors work in
two different genetic backgrounds of mice. Furthermore, in this
study we find that administration of ibrutinib (which inhibits
a significant number of kinases in addition to BTK, more
than acalabrutinib) in Xid-CLP mice neither results in further
beneficial effects nor any adverse effects on cardiac, renal, or
liver (dys)function. Inhibition of BTK reduces disease severity
in animal models of sepsis-induced lung injury (30, 31), warm
liver ischemia and reperfusion (32) and spontaneous lupus
nephritis (33). Thus, we here provide evidence that inhibition
of BTK alone is sufficient to prevent sepsis-induced multiple
organ injury.
BTK Inactivation Results in Enhanced
Bacterial Phagocytosis
We then investigated the mechanism(s) by which inactivation
of BTK protects mice against sepsis-induced multiple organ
failure. In septic patients, an essential treatment is early source
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FIGURE 8 | Expression of BTK is increased in whole human blood of septic non-survivor’s Original data was obtained from the gene expression omnibus under
dataset number GDS4971 which was published by Parnell et al. (26). Whole blood of patients confirmed with sepsis (and healthy participants) over a 5 day time
course. RNA was extracted from whole blood and analyzed for gene expression via microarray Illumina GenomeStudio V2010.3. Three groups were collected, healthy
participants, septic survivors, and septic non-survivors. (A) Time course of BTK expression. (B) Day 1 BTK expression. (C) Day 5 BTK expression. Data was
reanalysed looking for expression of BTK gene in their dataset and generated the figure using the software R, gene expression was quantile normalization and log
transformation of the data was applied. Significance was determined by one-way ANOVA followed by Bonferroni post hoc-test and a value of *P < 0.05 and ***P <
0.001 were considered significant. Data are expressed as mean ± SEM. Day 1 healthy (n = 18), septic survivors (n = 26), septic non-survivors (n = 9). Day 2 septic
survivors (n = 24), septic non-survivors (n = 7). Day 3 septic survivors (n = 22), septic non-survivors (n = 7). Day 4 septic survivors (n = 13), septic non-survivors (n =
5). Day 5 healthy (n = 18), septic survivors (n = 11), septic non-survivors (n = 3).
control (removal of infection), which is associated with improved
outcomes (34). We found that CLP in Xid mice results in
a reduction of the number of bacteria in both peritoneum
and blood (at 24 h after onset of CLP) when compared to
WT-CLP mice. This may well be due to an increase in
bacterial phagocytosis in Xid mice. Macrophages obtained from
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FIGURE 9 | Schematic diagram representing the role of Bruton’s tyrosine kinase (BTK) in the pathophysiology of sepsis. LPS is released from Gram-negative bacteria
which activate the TLR4 signaling pathway and the release of PepG from Gram-positive bacteria activate the TLR2 signaling pathway. BTK is involved in the activation
of TLR4 and TLR2 by binding to MyD88 and TRIF thus activating their representative signaling cascades. The activation of the MyD88 signaling pathway, leads to the
activation of NF-κB and the production of pro-inflammatory cytokines. Additionally, BTK activates the NLRP3 inflammasome by binding to the ASC component of the
inflammasome. Once active the NLRP3 inflammasome cleaves pro-IL-1β to active IL-1β. The production of chemokines from NF-κB activation results in the
recruitment of neutrophils and macrophages. Excessive inflammation from the cytokine storm and innate immune cells results in multiple organ failure/injury. The use
of BTK inhibitors such as ibrutinib or acalabrutinib supress sepsis-induced inflammation and thus multiple-organ failure/injury.
Xid-mice do not show defects in in phagocytosis (35, 36)
and we found that the percentage of phagocytosing cells are
similar in both WT and Xid mice. We discovered, however,
that macrophages obtained from Xid-mice with sepsis had
taken up a significantly larger number of bacteria. This was
also true for neutrophils from Xid-mice. We believe that
the increase in phagocytosis by macrophages and neutrophils
from Xid-mice in vivo could explain the observed increase
in clearance of bacteria in peritoneum and blood. Beguem
et al. (37) found that monocytes from healthy volunteers
stimulated with LPS and treated with evobrutinib resulted
in an increased rate of phagocytosis in vitro due to a
switch of macrophages from the pro-inflammatory M1 to
the pro-resolving M2 phenotype and this was associated
with reduced secretion of TNF-α. In addition, Xid mice
infected with Francisella tularensis showed enhanced bacterial
clearance from the lung and spleen, which correlated with a
significant improvement of survival when compared to wild-type
controls (38).
This raises the question of the underlying mechanisms that
enables or drives increased phagocytosis in Xid-mice? Neither
inhibition of BTK activity with ibrutinib nor inactivation of
BTK in Xid mice affects monocyte FcγR-mediated phagocytosis,
but it does supress FcγR-mediated cytokine production. The
decrease of calcium flux due to BTK inhibition also does not
affect phagocytosis, but does decrease cytokine production (35).
BTK inhibition results in the polarization to M2 macrophages
[which have greater phagocytic ability (39)], demonstrated
by increased expression of CD206. CD206 is involved in
phagocytosis of a number of bacterial strains. For example,
monocyte-derived macrophages that express high levels of
CD206 phagocytosed 78% of E. coli, while monocyte-derived
macrophages that express low levels of CD206 only phagocytosed
30% of E. coli (40). Excessive activation of neutrophils is
known to decrease survival and enhance susceptibility to
subsequent bacterial infections (41). One mechanism that
may contribute to the pathology of sepsis is the release of
neutrophil extracellular traps as they contain the beneficial
antimicrobial nuclear proteins but also damaging citrullinated
histones, elastase, myeloperoxidase and MMP-3 (42, 43). The
release of neutrophil extracellular traps results in ineffective
phagocytosis (44). Florence et al. (31) showed that BTK was
increased in the lung neutrophils and inhibiting BTK protected
mice against lethal influenza by reducing the release of neutrophil
extracellular traps. The decrease of neutrophil extracellular
traps was also observed in human peripheral blood neutrophils
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incubated with influenza and BTK inhibitor (31). However, the
exact molecular mechanisms underlying this phenomenon are
yet to be elucidated. Future studies are required to increase
our understanding as to how Xid macrophages and neutrophils
phagocytose more bacteria per immune cell.
BTK Inactivation Results in Reduced
Infiltration of the Peritoneum With Innate
Immune Cells
BTK plays a fundamental role in signaling and function of B
cells, but BTK is also highly expressed in myeloid cells such as
macrophages and neutrophils (9) and inactivation of BTK results
in reduced cell-mediated inflammatory responses (45, 46). We
report here that Xid-CLP mice have reduced infiltrating innate
immune cells (macrophages and neutrophils) in the peritoneum
(site of infection).We propose that this may lead to a reduction of
the formation of cytokines/chemokines in the serum and, hence,
will prevent the cytokines storm.
BTK Inactivation Results in M2 Polarization
Macrophages play an important role in the two phases
of sepsis (early pro-inflammatory phase and the later anti-
inflammatory phase), as they can have either pro-inflammatory
or anti-inflammatory properties. Initially, M1macrophages (pro-
inflammatory) activate inflammation by secreting TNF-α, IL-1β,
IL-6, and IL-12 to promote the removal of the pathogen, thenM2
macrophages repair tissue and resolve inflammation by secreting
cytokines including IL-10 (47, 48). If the M1 macrophage-driven
pro-inflammatory response cannot be controlled, the resultant
cytokine storm can be a key driver of the severity of sepsis
leading to organ failure and death (49). From our experiments
we conclude that a loss of function or inhibition of BTK drives
the switch from the pro-inflammatory M1 phenotype to pro-
resolving M2 phenotype in response to LPS (50). Here we
report that macrophages obtained from septic Xid-mice have
a pro-resolving M2 phenotype, whereas macrophages obtained
from septic WT-mice have the M1 phenotype. Most notably,
macrophages of the M2 phenotype have a greater phagocytotic
function resulting in increased clearance of apoptotic cells and an
acceleration of resolution (39). Indeed, M2 macrophages protect
against sepsis-induced lung injury (51) and sepsis-induced acute
kidney injury (52). Transplantation of M2 macrophages has been
suggested as a potential therapeutic approach for sepsis-induced
lung injury (51).
BTK Inactivation Reduces the Activation of
NF-κB
BTK plays a pivotal role in the activation of TLRs and,
hence, the signaling steps leading to the activation of NF-κB
(7), which plays a key role in the pathophysiology of septic
cardiomyopathy (53). Here we report that Xid mice subjected to
polymicrobial sepsis have a reduced activation of BTK and NF-
κB (measured as phosphorylation of IKKα/β and IκBα) in the
heart. We have previously reported that BTK inhibitors ibrutinib
or acalabrutinib reduce the activation of cardiac BTK and NF-
κB in mice subjected to sepsis (14). Furthermore, we have shown
that inhibition of NF-κB activation with an inhibitor of IKK also
attenuates the cardiac dysfunction associated with polymicrobial
sepsis (53). Purvis et al. (46) showed that ibrutinib treatment
attenuated the activation of NF-κB and gene expression of
cytokines in the diabetic kidney and liver. Thus, we propose
that an impairment in the activation of BTK in Xid mice leads
to reduced activation of NF-κB in the heart, which contributes
to or accounts for the observed reduction in organ injury and
dysfunction observed in Xid-mice with sepsis.
BTK Inactivation Prevents the Cytokine
Storm
Activation of NF-κB leads to an increase in the production
of cytokines and chemokines such as the pro-inflammatory
cytokines TNF-α, IL-6, IL-1β, and the anti-inflammatory
cytokine IL-10, neutrophils chemoattractant chemokines (KC
& ENA-78), monocyte chemoattractant chemokines (MCP-1,
MIP-1α, and MIP-1β) and G-CSF, all of which contribute to
the systemic inflammation and organ dysfunction associated
with sepsis (54). Out of all these cytokines, the ones increased
most in our model of murine sepsis were IL-6, KC, and MCP-
1. The levels of IL-8 and monocyte chemoattractant protein-1
(MCP-1) are associated with early 48 h and 28 day mortality in
sepsis patients (55). Most notably, we report that in Xid-mice
subjected to CLP-sepsis, all of these cytokines and chemokines
are markedly reduced. WT-CLP mice treated with ibrutinib
also show reduced production of sepsis-associated cytokines and
chemokines and no difference is observed with the addition
of ibrutinib to Xid-CLP mice. Thus, an impairment of BTK
activation in Xid-mice prevents NF-κB and NLRP3-dependent,
systemic inflammation (cytokine storm) resulting in a reduction
in organ injury/dysfunction.
BTK Inactivation Reduces the Activation of
the NLRP3 Inflammasome
BTK is also involved in the assembly/activation of the
NLRP3 inflammasome in both mice and humans (8, 56). The
activation of the NLRP3 inflammasome also plays a role in
the pathophysiology of sepsis and septic cardiomyopathy (57).
Pharmacological inhibition of NLRP3 activation with MCC950
(NLRP3 inflammasome inhibitor) reduced the neurological and
cognitive impairment in septic animals (58). It has also been
reported that genetic deficiency of NLRP3 promotes resolution
of inflammation in polymicrobial sepsis (59). We report here that
the activation of the NLRP3 inflammasome (measured as NLRP3
activation, caspase-1 activation and IL-1β release) was largely
reduced in Xid-mice subjected to CLP when compared to WT-
mice with sepsis. We previously reported that BTK inhibitors
(ibrutinib or acalabrutinib) inhibit the activation of the NLRP3
inflammasome and production of IL-1β in septic animals (14).
Purvis et al. (46) showed that ibrutinib treatment also attenuated
the activation NLRP3 inflammasome in the diabetic kidney and
liver. Thus, we propose that prevention of the activation of the
NLRP3 inflammasome secondary to reduced activation of BTK
importantly contributes to the reduction in inflammation and
organ dysfunction observed in septic Xid-mice.
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BTK Inactivation Restores Dysregulated
Metabolites
PCA showed that 49% of the total variance of all metabolites
formed three well separable clusters. The metabolomic profiles
of CLP-induced WT mice formed one cluster and was clearly
distinguishable from a second cluster (WT sham-operated and
Xid sham-operated) and a third cluster consisting of the three
groups Xid-CLP, WT-CLP+ ibrutinib, and Xid-CLP+ ibrutinib.
The common clustering of the latter three groups supports the
assumption that the inhibition of BTK alone is responsible for
the partial restoration of dysregulated metabolites in sepsis.
Host defense toward bacterial infection is a complex interplay
of several mechanisms including inflammation, coagulation,
immune activation, hypoxia, and metabolic reprogramming.
Specifically, the regulation and impact of themetabolic changes is
known to play an important role in the pathophysiology of sepsis
(60). We demonstrated in this study that deregulated members
of lipid mediators, phospholipids, primary metabolites and bile
acids in CLP-induced WT-mice were restored by ibrutinib
(in WT-mice) and/or by inactivation of the BTK gene (Xid-
mice). The elevated and reduced plasma levels of some restored
metabolites in the WT CLP group were already shown. For
example, an increased metabolism of the lipid mediators AA
and EPA could be found in plasma of sepsis patients (61). In
addition, two other lipid mediators, OEA and lyso-PAF, were
decreased in CLP-induced WT mice. Platelet-activating factor
(PAF) is a proinflammatory mediator in systemic inflammation
and its known to be upregulated in sepsis (62). Degradation
of the immediate precursor lyso-PAF is probably a result
of its increased transformation to PAF (63). The decreased
levels of the lipid-amide OEA are probably a compensatory
mechanism in sepsis-related weight loss and disturbed energy
balance, because OEA is a modulator in food consumption
and weight management and actually leads to satiation or
meal termination (64). Even the restoration of the reduced
bile acid TDCA and the elevated amino acid DOPA seems
to be a positive regulatory mechanism. TDCA ameliorates
systemic inflammation, normalizes blood pressure, prevents
kidney injury, and prolongs survival in a mouse sepsis model
(65). DOPA has anti-neuro inflammation effects and improved
neuroplasticity in septic mice (66). The plasma of the WT-
CLP group showed also increased levels of isoforms of the
phospholipids species lysophaphatidylserine and PS, probably
due to their procoagulant activity in sepsis (67, 68). Some
primary metabolites were also enhanced in septic mice and
restored by ibrutinib administration and BTK inactivation such
as the dysregulated precursors (cytosine, niacinamide, nicotinic
acid) of nucleotide or nicotinate and nicotinamide metabolism
(69, 70). The restoration also included the loss of carnosine to
plasma due to skeletal muscle wasting in sepsis (71) and the
elevated levels of creatine presumably because of the known
higher activity of creatine kinase to catalyze the urgently required
ATP in developing sepsis (72). This data of restored metabolites
demonstrates that Xid mice with a deficiency in BTK have a
similar metabolomic profile in sepsis than WT-CLP-mice treated
with ibrutinib.
In addition, the data in Figures S5,S6 reveal that Xid mice
restored metabolites 7 times more than ibrutinib-treated mice
(Figure S7). Many of the additionally restored metabolites in
Xid mice are known to be deregulated in sepsis such as adenine
(73) creatinine (74), and kynurenine (75). An explanation for
the different magnitude of restored metabolites in Xid mice in
comparison with ibrutinib-treated mice could be the different
number of inhibited kinases. Thus, the Xid mice seem to benefit
from the inhibition of only one kinase, namely BTK, which in
addition to reducing cytokine storm restores the sepsis-related
dysregulation of specific metabolites.
BTK Expression Is Increased in Whole
Human Blood of Septic Non-survivors
Currently the expression and/or activation of BTK in septic
patients has not been reported. There are datasets available on the
GEO and we reanalysed microarray data (GDS4971) of the time
course of gene expression in healthy, septic survivors, and septic
non-survivors published by Parnell et al. (26). Interestingly, our
analysis revealed an increase in expression of BTK in septic
non-survivors, whereas BTK expression in septic survivors does
not increase and is not different from healthy volunteers. Thus,
increases in BTK expression in septic patients correlate with
mortality, while lower levels of BTK expression are associated
with survival from sepsis. There were no clear differences
between cytokine expression of TNF-α, IL-6, MCP-1, CXCL1 in
the three groups, expression of BTK was a better predictor of
mortality rather than with the expression of any one cytokine.
We have previously shown in septic mouse hearts that activation
of BTK correlates with cardiac dysfunction (14). BTK activation
also increases in whole blood of COVID-19 patients which, like
septic patients, also present with excessive systemic inflammation
(cytokine storm) (17).
LIMITATIONS OF THE STUDY
We have shown that Xid-mice subjected to CLP have increased
bacterial clearance and reduced systemic inflammation
(secondary to reduced activation of the NLRP3 inflammasome
and NF-κB) and cardiac (organ) dysfunction. There is good
evidence that mortality of patients with sepsis increases with an
increase in the number of organs failing (SOFA scores). In the
UK survival studies in septic models are not routinely conducted
due to ethical reasons. Thus, we were unable to investigate the
survival of Xid mice undergoing sepsis. It has been reported that
a reduction in temperature <30◦C or a change of temperature
of 5◦C over time predicts mortality in animals with sepsis
(29). Using this more humane surrogate marker, we found that
Xid mice with sepsis have a predicted mortality of 0% (100%
survival), while WT-mice with sepsis would have a predicted
mortality of 90% (10% survival). We found that ibrutinib does
not affect predicted mortality in Xid-CLP resulting in a predicted
mortality of 0% (100% survival) and that delayed administration
of ibrutinib in WT-CLP mice led to a predicated mortality of
15% (85% survival). It would be useful to confirm the impact
Frontiers in Immunology | www.frontiersin.org 17 October 2020 | Volume 11 | Article 581758
O’Riordan et al. Xid-Mice Are Protected From Sepsis
of an impairment in BTK function in Xid-mice on outcome
(mortality) in a more long-term sepsis model.
CONCLUSION
We report here for the first time that genetic inactivation of
BTK is responsible for conferring protection against multiple
organ failure in a clinically relevant model of sepsis. Most
importantly we have shown that the inactivation of BTK
in Xid mice results in an increase of bacterial phagocytosis
in macrophages and neutrophils, thus, increasing bacterial
clearance in both peritoneum and blood. Inactivation of BTK
also results in a phenotypic switch of macrophages from
M1 to the M2 phenotype, which aids in the resolution of
sepsis. The suppression of the immune system by inactivated
BTK leads to reduced activation of NF-κB and the NLRP3
inflammasome, therefore, preventing the induction of the
cytokine storm. Metabolomic analysis revealed a dysregulation
of metabolites in WT septic mice. Most notably, we found
that inactivation of BTK in Xid-mice or administration of
ibrutinib in WT mice is responsible for the (partial) restoration
of dysregulated metabolites in sepsis. As the administration of
ibrutinib to Xid-CLP mice did not result in any additional
(beneficial) effects on the alterations in organ dysfunction,
cytokine/chemokines formation and changes in metabolites
caused by sepsis, our data strongly suggest that BTK inactivation
is responsible for the observed effects of ibrutinib. Lastly,
we have found that BTK expression in humans is increased
in the blood of septic non-survivors, while lower expression
is associated with survival from sepsis. Taken together our
work suggests that BTK inhibitors maybe repurposed for the
use in sepsis (or other conditions associated with excessive
local or systemic inflammation including COVID-19) due to
their ability to reduce systemic inflammation (cytokine storm),
their ability to enhance the phagocytosis of macrophages and
switch macrophages from the pro-inflammatory M1 to the anti-
inflammatory M2 phenotype.
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